Recently, Cubist Pharmaceuticals (CBST) decided to acquire a privately held biopharmaceutical company Calixa Therapeutics for an upfront payment of $92.5 million. Additionally, Cubist would be required to make a payment of another $310 million on the achievement of certain development, regulatory, and commercial milestones. Calixa is primarily focused on the development of antibiotics to [...] (CBST) Cubist to Aquire Calixa Therapeutics